Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells
用于消除 HIV 储存细胞的双特异性和三特异性抗 Env 抗体
基本信息
- 批准号:10224769
- 负责人:
- 金额:$ 71.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-10 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdultAffinityAntibodiesAntibody TherapyAntiviral AgentsBerlinBindingBiological ModelsBispecific AntibodiesBone Marrow TransplantationCCR5 geneCell surfaceCellsChronicClinicalCollectionDiagnosisDrug KineticsEarly treatmentEngineeringEpitopesFranceGoalsHIVHIV-1HourIgG1InfectionInvestigationKnowledgeLibrariesMeasuresMediatingMississippiMutationPathway interactionsPatientsPopulationPopulation HeterogeneityPreventionPropertyProvirusesResearch PersonnelSeriesSleepTimeUrsidae FamilyViralVirionVirusVirus DiseasesVirus LatencyWhole-Body Irradiationacute infectionantibody engineeringantibody-dependent cell cytotoxicityantigen bindingantiretroviral therapyarmcell killingchemotherapyclinical candidateclinical developmentcohortdesignefficacy evaluationexperienceexperimental studyfightinghumanized mouseimprovedin vitro activityin vivolatent HIV reservoirlead candidatemouse modelneutralizing antibodynovel therapeuticspreventpurgescreeningspatial relationshipstem cellsviral reboundweapons
项目摘要
PROJECT SUMMARY/ABSTRACT
Antibodies constitute a powerful weapon to fight viral infections. They could neutralize the infectivity of virus
particles as well as mediate killing of productively infected cells via mechanisms such as antibody-dependent
cell-mediated cytotoxicity (ADCC). In the past five years, our group has utilized the advances made in the
antibody engineering field, as well as the growing lists of broadly neutralization antibodies (bNAbs) identified by
other investigators, to construct new bispecific antibodies that have exquisite antiviral breadth and potency for
the purpose of HIV-1 prevention. Now, with this proposal, we wish to expand our antibody engineering effort to
generate a collection of bispecific and trispecific antibodies that are optimized for killing of Env-expressing
cells, and for important properties such as pharmacokinetics. Instead of screening for virus-neutralization
activity as we have previously done, we will now engineer and screen a library of Env-targeting multi-specific
antibodies for cell-binding and cell-killing activities in vitro. The best performing antibody constructs will then
be evaluated systematically in vivo in a humanized mouse model for the effect on their cell-killing capacity,
their ability to restrict or eliminate latent reservoir cells after activation, and their ability to prevent or limit the
establishment of the HIV-1 latent reservoir. Along with our knowledge of HIV-1 bNAbs and antibody
engineering, our deep understanding of viral dynamics and our prior experience studying the HIV-1 latent
reservoir will be brought to bear on the design, conduct, and interpretation of experiments to evaluate and
quantify the antiviral effects of our top antibody constructs in humanized mice.
Our group has successfully engineered two bispecific antibodies with exquisite HIV-1-neutralizing activity, and
we have since extended our know-how in antibody engineering to the construction of bispecific or trispecific
antibodies that target Env for the purpose of facilitating the elimination of infected cells. In the end, we hope to
offer to the field one or two multi-specific antibodies that could be applied toward the elimination of latent
reservoir cells as one critical component of a multi-pronged approach to HIV-1 eradication.
项目总结/摘要
抗体是对抗病毒感染的有力武器。它们可以中和病毒的传染性
颗粒以及介导通过抗体依赖性的机制,
细胞介导的细胞毒性(ADCC)。在过去的五年里,我们的团队利用了在
抗体工程领域,以及越来越多的广泛中和抗体(bNAb)的名单确定,
其他研究人员,以构建新的双特异性抗体,具有精致的抗病毒广度和效力,
预防HIV-1的目的。现在,有了这个建议,我们希望扩大我们的抗体工程努力,
产生双特异性和三特异性抗体的集合,所述抗体被优化用于杀死表达Env的
细胞,以及重要的性质,如药代动力学。而不是筛选病毒中和
正如我们以前所做的那样,我们现在将设计和筛选一个Env靶向多特异性
用于体外细胞结合和细胞杀伤活性的抗体。然后,表现最好的抗体构建体将
在人源化小鼠模型中系统地评价其对细胞杀伤能力的影响,
它们在激活后限制或消除潜伏储库细胞的能力,以及它们防止或限制
建立HIV-1潜伏库。沿着我们对HIV-1 bNAb和抗体的了解
工程,我们对病毒动力学的深刻理解和我们之前研究HIV-1潜伏的经验,
储层将承担的设计,进行,和解释的实验,以评估和
量化我们的顶级抗体构建体在人源化小鼠中的抗病毒效果。
我们的团队已经成功地设计了两种具有精致的HIV-1中和活性的双特异性抗体,
从那时起,我们已经将我们在抗体工程方面的专业知识扩展到双特异性或三特异性抗体的构建。
靶向Env的抗体,目的是促进受感染细胞的消除。最后,我们希望
为该领域提供一种或两种多特异性抗体,其可用于消除潜在的
作为根除HIV-1的多管齐下方法的一个关键组成部分。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID D HO其他文献
DAVID D HO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID D HO', 18)}}的其他基金
Multiplex Small Molecule Discovery to Identify Broad-Acting Viral Protease Inhibitors
多重小分子发现来鉴定广泛作用的病毒蛋白酶抑制剂
- 批准号:
10513925 - 财政年份:2022
- 资助金额:
$ 71.39万 - 项目类别:
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.
体内量化抗 HIV IgG1 抗体的效应器功能。
- 批准号:
10078502 - 财政年份:2019
- 资助金额:
$ 71.39万 - 项目类别:
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.
体内量化抗 HIV IgG1 抗体的效应器功能。
- 批准号:
10239076 - 财政年份:2019
- 资助金额:
$ 71.39万 - 项目类别:
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.
体内量化抗 HIV IgG1 抗体的效应器功能。
- 批准号:
10866743 - 财政年份:2019
- 资助金额:
$ 71.39万 - 项目类别:
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.
体内量化抗 HIV IgG1 抗体的效应器功能。
- 批准号:
10005113 - 财政年份:2019
- 资助金额:
$ 71.39万 - 项目类别:
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir
用于选择性靶向和激活 HIV 潜伏库的双特异性抗体药物偶联物
- 批准号:
10078006 - 财政年份:2017
- 资助金额:
$ 71.39万 - 项目类别:
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells
用于消除 HIV 储存细胞的双特异性和三特异性抗 Env 抗体
- 批准号:
10083601 - 财政年份:2017
- 资助金额:
$ 71.39万 - 项目类别:
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent Reservoir
用于选择性靶向和激活 HIV 潜伏库的双特异性抗体药物偶联物
- 批准号:
10222490 - 财政年份:2017
- 资助金额:
$ 71.39万 - 项目类别:
Combination Clostridium Difficile Toxin and Adhesin Vaccine
艰难梭菌毒素和粘附素联合疫苗
- 批准号:
8686731 - 财政年份:2012
- 资助金额:
$ 71.39万 - 项目类别:
Combination Clostridium Difficile Toxin and Adhesin Vaccine
艰难梭菌毒素和粘附素联合疫苗
- 批准号:
8290921 - 财政年份:2012
- 资助金额:
$ 71.39万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 71.39万 - 项目类别:
Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 71.39万 - 项目类别:
Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 71.39万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 71.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 71.39万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 71.39万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 71.39万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 71.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 71.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 71.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)